CA
NZ
UK
AU
IND
US
…
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11207 for the treatment of Parkinson's disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aeolus Pharmaceuticl (AOLS.US) is an OTC Pink-listed company that appears to operate in the pharmaceutical/biotech sector but has limited public disclosure. If the company is engaged in drug development or specialty therapeutics, long-term growth drivers could include clinical progress, regulatory approvals, licensing deals and successful commercialization, which may benefit shareholders.
The principal investment risks are high execution and regulatory risk inherent to drug development, likely limited liquidity and market depth on the Pink market, and significant financing and operational uncertainty for a small OTC-listed company.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Depreciation and amortization | 0.17M | 0.23M | 0.24M | 0.21M | 0.17M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Breakdown | 2016-09-30 | 2015-09-30 | 2014-09-30 | 2013-09-30 | 2012-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2016-09-30 | 2015-09-30 | 2014-09-30 | 2013-09-30 | 2012-09-30 |
| Change to liabilities | -0.65M | -0.38M | 0.73M | -1.01M | 0.13M |
| Net borrowings | - | 1.00M | 1.00M | 1.00M | - |
| Total cash from financing activities | 6.17M | 1.02M | 0.33M | 3.56M | 0.64M |
| Change to operating activities | -0.16M | 0.41M | 0.22M | -0.54M | - |
| Net income | -3.56M | -2.63M | -0.08M | -3.21M | 1.70M |
| Change in cash | 3.06M | -1.42M | 0.65M | 0.59M | -0.24M |
| Begin period cash flow | 0.09M | 1.52M | 0.87M | 0.28M | 0.52M |
| End period cash flow | 3.15M | 0.09M | 1.52M | 0.87M | 0.28M |
| Total cash from operating activities | -3.11M | -2.44M | 0.32M | -2.97M | -0.88M |
| Depreciation | 0.28M | 0.28M | 0.28M | 0.01M | 0.01M |
| Change to account receivables | 0.83M | -0.03M | -1.19M | 0.41M | 0.80M |
| Sale purchase of stock | 2.00M | 0.02M | 0.33M | -0.06M | -0.02M |
| Other cashflows from financing activities | -0.34M | -0.34M | -0.34M | -0.06M | - |
| Change to netincome | 0.14M | 0.18M | 0.64M | 1.37M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change receivables | 0.83M | -0.02M | -1.19M | - | - |
| Cash flows other operating | 0.10M | 0.00M | -0.01M | - | - |
| Cash and cash equivalents changes | 3.06M | -1.42M | 0.65M | - | - |
| Change in working capital | 0.02M | 0.01M | -0.23M | -1.14M | 0.92M |
| Stock based compensation | - | - | - | - | 0.57M |
| Other non cash items | 0.43M | 0.18M | 0.64M | 1.37M | -4.07M |
| Free cash flow | -3.11M | -2.44M | 0.32M | -2.97M | -0.88M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AOLS Aeolus Pharmaceuticl |
- -% |
0.00 | - | - | 0.02 | 0.81 | 0.22 | -0.04 |
| MKKGY Merck KGaA ADR |
0.17 0.53% |
32.25 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
161.82 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.16 0.78% |
20.27 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.22 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11207 for the treatment of Parkinson's disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
27800 Medical Center Rd, Mission Viejo, CA, United States, 92691
949 485 9621
4
| Name | Title | Year Born |
|---|---|---|
| Mr. John L. Mcmanus | Chief Exec. Officer and Pres | 1964 |
| Mr. Christopher Stanley | VP of Operations | NA |
| Mr. John L. Mcmanus | Chief Executive Officer and President | 1964 |
| Mr. Christopher Stanley | Vice President of Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...